XW0: Introduction — Anatomical RegionsPutting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
0 SkinX External2 Anacaulase-bcdb7 New Technology Group 71 Subcutaneous Tissue3 Percutaneous1 Daratumumab and Hyaluronidase-fihj8 New Technology Group 81 Subcutaneous Tissue3 Percutaneous2 Talquetamab Antineoplastic9 New Technology Group 91 Subcutaneous Tissue3 Percutaneous4 Teclistamab Antineoplastic8 New Technology Group 81 Subcutaneous Tissue3 Percutaneous6 DasiglucagonA New Technology Group 101 Subcutaneous Tissue3 Percutaneous9 Satralizumab-mwge7 New Technology Group 71 Subcutaneous Tissue3 PercutaneousF Other New Technology Therapeutic Substance5 New Technology Group 51 Subcutaneous Tissue3 PercutaneousG REGN-COV2 Monoclonal Antibody; H Other New Technology Monoclonal Antibody; K Leronlimab Monoclonal Antibody6 New Technology Group 61 Subcutaneous Tissue3 PercutaneousL Elranatamab Antineoplastic9 New Technology Group 91 Subcutaneous Tissue3 PercutaneousS COVID-19 Vaccine Dose 16 New Technology Group 61 Subcutaneous Tissue3 PercutaneousS Epcoritamab Monoclonal Antibody9 New Technology Group 91 Subcutaneous Tissue3 PercutaneousT COVID-19 Vaccine Dose 26 New Technology Group 61 Subcutaneous Tissue3 PercutaneousT Rozanolixizumab-noli Monoclonal AntibodyB New Technology Group 111 Subcutaneous Tissue3 PercutaneousU COVID-19 Vaccine6 New Technology Group 61 Subcutaneous Tissue3 PercutaneousV COVID-19 Vaccine Dose 37 New Technology Group 71 Subcutaneous Tissue3 PercutaneousW Caplacizumab5 New Technology Group 51 Subcutaneous Tissue3 PercutaneousW COVID-19 Vaccine Booster7 New Technology Group 71 Subcutaneous TissueX External2 Anacaulase-bcdb7 New Technology Group 72 Muscle0 OpenD Engineered Allogeneic Thymus Tissue8 New Technology Group 82 Muscle3 PercutaneousS COVID-19 Vaccine Dose 1; T COVID-19 Vaccine Dose 2; U COVID-19 Vaccine6 New Technology Group 62 Muscle3 PercutaneousV COVID-19 Vaccine Dose 3; W COVID-19 Vaccine Booster; X Tixagevimab and Cilgavimab Monoclonal Antibody; Y Other New Technology Monoclonal Antibody7 New Technology Group 73 Peripheral Vein3 Percutaneous0 Spesolimab Monoclonal Antibody8 New Technology Group 83 Peripheral Vein3 Percutaneous3 Bentracimab, Ticagrelor Reversal Agent; 4 Cefepime-taniborbactam Anti-infectiveA New Technology Group 103 Peripheral Vein3 Percutaneous5 Narsoplimab Monoclonal Antibody7 New Technology Group 73 Peripheral Vein3 Percutaneous5 Mosunetuzumab Antineoplastic8 New Technology Group 83 Peripheral Vein3 Percutaneous5 Ceftobiprole Medocaril Anti-infectiveA New Technology Group 103 Peripheral Vein3 Percutaneous6 Terlipressin7 New Technology Group 73 Peripheral Vein3 Percutaneous6 Afamitresgene Autoleucel Immunotherapy8 New Technology Group 83 Peripheral Vein3 Percutaneous7 Coagulation Factor Xa, Inactivated2 New Technology Group 23 Peripheral Vein3 Percutaneous7 Trilaciclib7 New Technology Group 73 Peripheral Vein3 Percutaneous7 Tabelecleucel Immunotherapy8 New Technology Group 83 Peripheral Vein3 Percutaneous8 Lurbinectedin7 New Technology Group 73 Peripheral Vein3 Percutaneous8 Treosulfan8 New Technology Group 83 Peripheral Vein3 Percutaneous8 Obecabtagene AutoleucelA New Technology Group 103 Peripheral Vein3 Percutaneous9 Ceftolozane/Tazobactam Anti-infective6 New Technology Group 63 Peripheral Vein3 Percutaneous9 Inebilizumab-cdon8 New Technology Group 83 Peripheral Vein3 Percutaneous9 Odronextamab AntineoplasticA New Technology Group 103 Peripheral Vein3 PercutaneousA Ciltacabtagene Autoleucel7 New Technology Group 73 Peripheral Vein3 PercutaneousB Cytarabine and Daunorubicin Liposome Antineoplastic3 New Technology Group 33 Peripheral Vein3 PercutaneousB Amivantamab Monoclonal Antibody7 New Technology Group 73 Peripheral Vein3 PercutaneousB Orca-T Allogeneic T-cell ImmunotherapyA New Technology Group 103 Peripheral Vein3 PercutaneousC Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous7 New Technology Group 73 Peripheral Vein3 PercutaneousC Zanidatamab Antineoplastic; D Donislecel-jujn Allogeneic Pancreatic Islet Cellular SuspensionA New Technology Group 103 Peripheral Vein3 PercutaneousE Remdesivir Anti-infective5 New Technology Group 53 Peripheral Vein3 PercutaneousF Other New Technology Therapeutic Substance3 New Technology Group 33 Peripheral Vein3 PercutaneousF Other New Technology Therapeutic Substance5 New Technology Group 53 Peripheral Vein3 PercutaneousF Non-Chimeric Antigen Receptor T-cell Immune Effector Cell TherapyA New Technology Group 103 Peripheral Vein3 PercutaneousF Valoctocogene Roxaparvovec-rvoxB New Technology Group 113 Peripheral Vein3 PercutaneousG Sarilumab5 New Technology Group 53 Peripheral Vein3 PercutaneousG REGN-COV2 Monoclonal Antibody6 New Technology Group 63 Peripheral Vein3 PercutaneousG Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic7 New Technology Group 73 Peripheral Vein3 PercutaneousH Tocilizumab5 New Technology Group 53 Peripheral Vein3 PercutaneousH Other New Technology Monoclonal Antibody6 New Technology Group 63 Peripheral Vein3 PercutaneousH Axicabtagene Ciloleucel Immunotherapy; J Tisagenlecleucel Immunotherapy; K Idecabtagene Vicleucel Immunotherapy7 New Technology Group 73 Peripheral Vein3 PercutaneousK Sulbactam-Durlobactam9 New Technology Group 93 Peripheral Vein3 PercutaneousL CD24Fc Immunomodulator6 New Technology Group 63 Peripheral Vein3 PercutaneousL Lifileucel Immunotherapy; M Brexucabtagene Autoleucel Immunotherapy7 New Technology Group 73 Peripheral Vein3 PercutaneousM Emapalumab-lzsg Anti-IFNy Monoclonal AntibodyA New Technology Group 103 Peripheral Vein3 PercutaneousN Lisocabtagene Maraleucel Immunotherapy7 New Technology Group 73 Peripheral Vein3 PercutaneousN Tarlatamab-dlle AntineoplasticA New Technology Group 103 Peripheral Vein3 PercutaneousP Glofitamab Antineoplastic9 New Technology Group 93 Peripheral Vein3 PercutaneousP Aztreonam-avibactam Anti-infectiveB New Technology Group 113 Peripheral Vein3 PercutaneousQ Tagraxofusp-erzs Antineoplastic5 New Technology Group 53 Peripheral Vein3 PercutaneousQ Posoleucel9 New Technology Group 93 Peripheral Vein3 PercutaneousQ IloprostB New Technology Group 113 Peripheral Vein3 PercutaneousR Rezafungin9 New Technology Group 93 Peripheral Vein3 PercutaneousR Letetresgene AutoleucelB New Technology Group 113 Peripheral Vein3 PercutaneousS Iobenguane I-131 Antineoplastic; W Caplacizumab5 New Technology Group 53 Peripheral Vein3 PercutaneousW Fosfomycin Anti-infectiveB New Technology Group 114 Central Vein3 Percutaneous0 Spesolimab Monoclonal Antibody8 New Technology Group 84 Central Vein3 Percutaneous3 Bentracimab, Ticagrelor Reversal Agent; 4 Cefepime-taniborbactam Anti-infectiveA New Technology Group 104 Central Vein3 Percutaneous5 Narsoplimab Monoclonal Antibody7 New Technology Group 74 Central Vein3 Percutaneous5 Mosunetuzumab Antineoplastic8 New Technology Group 84 Central Vein3 Percutaneous5 Ceftobiprole Medocaril Anti-infectiveA New Technology Group 104 Central Vein3 Percutaneous6 Terlipressin7 New Technology Group 74 Central Vein3 Percutaneous6 Afamitresgene Autoleucel Immunotherapy8 New Technology Group 84 Central Vein3 Percutaneous7 Coagulation Factor Xa, Inactivated2 New Technology Group 24 Central Vein3 Percutaneous7 Trilaciclib7 New Technology Group 74 Central Vein3 Percutaneous7 Tabelecleucel Immunotherapy8 New Technology Group 84 Central Vein3 Percutaneous8 Lurbinectedin7 New Technology Group 74 Central Vein3 Percutaneous8 Treosulfan8 New Technology Group 84 Central Vein3 Percutaneous8 Obecabtagene AutoleucelA New Technology Group 104 Central Vein3 Percutaneous9 Ceftolozane/Tazobactam Anti-infective6 New Technology Group 64 Central Vein3 Percutaneous9 Inebilizumab-cdon8 New Technology Group 84 Central Vein3 Percutaneous9 Odronextamab AntineoplasticA New Technology Group 104 Central Vein3 PercutaneousA Ciltacabtagene Autoleucel7 New Technology Group 74 Central Vein3 PercutaneousB Cytarabine and Daunorubicin Liposome Antineoplastic3 New Technology Group 34 Central Vein3 PercutaneousB Amivantamab Monoclonal Antibody7 New Technology Group 74 Central Vein3 PercutaneousB Orca-T Allogeneic T-cell ImmunotherapyA New Technology Group 104 Central Vein3 PercutaneousC Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous7 New Technology Group 74 Central Vein3 PercutaneousC Zanidatamab AntineoplasticA New Technology Group 104 Central Vein3 PercutaneousE Remdesivir Anti-infective5 New Technology Group 54 Central Vein3 PercutaneousF Other New Technology Therapeutic Substance3 New Technology Group 34 Central Vein3 PercutaneousF Other New Technology Therapeutic Substance5 New Technology Group 54 Central Vein3 PercutaneousF Non-Chimeric Antigen Receptor T-cell Immune Effector Cell TherapyA New Technology Group 104 Central Vein3 PercutaneousF Valoctocogene Roxaparvovec-rvoxB New Technology Group 114 Central Vein3 PercutaneousG Sarilumab5 New Technology Group 54 Central Vein3 PercutaneousG REGN-COV2 Monoclonal Antibody6 New Technology Group 64 Central Vein3 PercutaneousG Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic7 New Technology Group 74 Central Vein3 PercutaneousH Tocilizumab5 New Technology Group 54 Central Vein3 PercutaneousH Other New Technology Monoclonal Antibody6 New Technology Group 64 Central Vein3 PercutaneousH Axicabtagene Ciloleucel Immunotherapy; J Tisagenlecleucel Immunotherapy; K Idecabtagene Vicleucel Immunotherapy7 New Technology Group 74 Central Vein3 PercutaneousK Sulbactam-Durlobactam9 New Technology Group 94 Central Vein3 PercutaneousL CD24Fc Immunomodulator6 New Technology Group 64 Central Vein3 PercutaneousL Lifileucel Immunotherapy; M Brexucabtagene Autoleucel Immunotherapy7 New Technology Group 74 Central Vein3 PercutaneousM Emapalumab-lzsg Anti-IFNy Monoclonal AntibodyA New Technology Group 104 Central Vein3 PercutaneousN Lisocabtagene Maraleucel Immunotherapy7 New Technology Group 74 Central Vein3 PercutaneousN Tarlatamab-dlle AntineoplasticA New Technology Group 104 Central Vein3 PercutaneousP Glofitamab Antineoplastic9 New Technology Group 94 Central Vein3 PercutaneousP Aztreonam-avibactam Anti-infectiveB New Technology Group 114 Central Vein3 PercutaneousQ Tagraxofusp-erzs Antineoplastic5 New Technology Group 54 Central Vein3 PercutaneousQ Posoleucel9 New Technology Group 94 Central Vein3 PercutaneousQ IloprostB New Technology Group 114 Central Vein3 PercutaneousR Rezafungin9 New Technology Group 94 Central Vein3 PercutaneousR Letetresgene AutoleucelB New Technology Group 114 Central Vein3 PercutaneousS Iobenguane I-131 Antineoplastic; W Caplacizumab5 New Technology Group 54 Central Vein3 PercutaneousW Fosfomycin Anti-infectiveB New Technology Group 115 Peripheral Artery3 PercutaneousT Melphalan Hydrochloride Antineoplastic9 New Technology Group 9D Mouth and PharynxX External3 Maribavir Anti-infective8 New Technology Group 8D Mouth and PharynxX External8 Uridine Triacetate2 New Technology Group 2D Mouth and PharynxX ExternalF Other New Technology Therapeutic Substance5 New Technology Group 5D Mouth and PharynxX ExternalJ Quizartinib Antineoplastic9 New Technology Group 9D Mouth and PharynxX ExternalK Sabizabulin8 New Technology Group 8D Mouth and PharynxX ExternalM Baricitinib6 New Technology Group 6D Mouth and PharynxX ExternalN SER-1099 New Technology Group 9D Mouth and PharynxX ExternalR Fostamatinib7 New Technology Group 7D Mouth and PharynxX ExternalV Xanomeline and Trospium ChlorideB New Technology Group 11G Upper GI7 Via Natural or Artificial Opening3 Maribavir Anti-infective; K Sabizabulin8 New Technology Group 8G Upper GI7 Via Natural or Artificial OpeningM Baricitinib6 New Technology Group 6G Upper GI7 Via Natural or Artificial OpeningR Fostamatinib7 New Technology Group 7G Upper GI8 Via Natural or Artificial Opening Endoscopic8 Mineral-based Topical Hemostatic Agent6 New Technology Group 6H Lower GI7 Via Natural or Artificial Opening3 Maribavir Anti-infective; K Sabizabulin8 New Technology Group 8H Lower GI7 Via Natural or Artificial OpeningM Baricitinib6 New Technology Group 6H Lower GI7 Via Natural or Artificial OpeningR Fostamatinib7 New Technology Group 7H Lower GI7 Via Natural or Artificial OpeningX Broad Consortium Microbiota-based Live Biotherapeutic Suspension8 New Technology Group 8H Lower GI8 Via Natural or Artificial Opening Endoscopic8 Mineral-based Topical Hemostatic Agent6 New Technology Group 6J Coronary Artery, One Artery; K Coronary Artery, Two Arteries; L Coronary Artery, Three Arteries; M Coronary Artery, Four or More Arteries3 PercutaneousH Paclitaxel-Coated Balloon Technology, One Balloon; J Paclitaxel-Coated Balloon Technology, Two Balloons; K Paclitaxel-Coated Balloon Technology, Three Balloons; L Paclitaxel-Coated Balloon Technology, Four or More BalloonsA New Technology Group 10Q Cranial Cavity and Brain3 Percutaneous1 Eladocagene exuparvovec6 New Technology Group 6U Joints0 OpenG Vancomycin Hydrochloride and Tobramycin Sulfate Anti-Infective, Temporary Irrigation Spacer SystemA New Technology Group 10U Joints0 Open; 3 Percutaneous; 4 Percutaneous EndoscopicX Peptide Enhanced Bone Void FillerB New Technology Group 11V Bones0 OpenP Antibiotic-eluting Bone Void Filler7 New Technology Group 7V Bones3 PercutaneousW AGN1 Bone Void FillerA New Technology Group 10